Background. Data regarding the management and outcome of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to 1st-line imatinib and 2nd-line sunitinib are limited. Methods. Medical records of 223 imatinib-resistant and sunitinib-resistant GIST who were treated in 11 major referral centers were reviewed. Results. The three most frequent drugs used in the 3rd-line setting were: nilotinib n = 67 (29.5%), sorafenib n = 55 (24.5%), and imatinib n = 40 (17.5%). There were 18 patients (8%) who received best supportive care (BSC) only. The median progression-free survival (PFS) and overall survival (OS) on 3rd-line treatment were 3.6 months [95% confidence interval (95% CI), 3.1-4.1] and 9.2 months (95% CI, 7.5-10.9), respe...
Gastrointestinal stromal tumors (GISTs) originate from interstitial cells of Cajal and account for o...
Aim of the study was to analyze the outcome of treatment and factors predicting results of sorafeni...
Tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of unresectable and metastatic...
BACKGROUND: Data regarding the management and outcome of patients with metastatic gastrointestinal s...
BACKGROUND: Data regarding the management and outcome of patients with metasta...
Imatinib, a selective tyrosine kinase inhibitor, is currently the standard of care first-line treatm...
BACKGROUND: The prognosis of patients with advanced gastrointestinal stromal tumor (GIST) has improv...
Tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of unresectable and metastatic...
Tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of unresectable and metastatic...
Rechallenge with imatinib is an option in advanced gastrointestinal stromal tumor (GIST) patients fo...
The introduction of the tyrosine kinase inhibitor imatinib has transformed the therapy of advanced o...
Patients diagnosed with advanced gastrointestinal stromal tumours (GISTs) who are resistant or intol...
Background: Although most patients with gastrointestinal stromal tumor (GIST) treated with imatinib ...
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors. Currently, it is possible to ca...
Patients diagnosed with advanced gastrointestinal stromal tumours (GISTs) who are resistant or intol...
Gastrointestinal stromal tumors (GISTs) originate from interstitial cells of Cajal and account for o...
Aim of the study was to analyze the outcome of treatment and factors predicting results of sorafeni...
Tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of unresectable and metastatic...
BACKGROUND: Data regarding the management and outcome of patients with metastatic gastrointestinal s...
BACKGROUND: Data regarding the management and outcome of patients with metasta...
Imatinib, a selective tyrosine kinase inhibitor, is currently the standard of care first-line treatm...
BACKGROUND: The prognosis of patients with advanced gastrointestinal stromal tumor (GIST) has improv...
Tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of unresectable and metastatic...
Tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of unresectable and metastatic...
Rechallenge with imatinib is an option in advanced gastrointestinal stromal tumor (GIST) patients fo...
The introduction of the tyrosine kinase inhibitor imatinib has transformed the therapy of advanced o...
Patients diagnosed with advanced gastrointestinal stromal tumours (GISTs) who are resistant or intol...
Background: Although most patients with gastrointestinal stromal tumor (GIST) treated with imatinib ...
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors. Currently, it is possible to ca...
Patients diagnosed with advanced gastrointestinal stromal tumours (GISTs) who are resistant or intol...
Gastrointestinal stromal tumors (GISTs) originate from interstitial cells of Cajal and account for o...
Aim of the study was to analyze the outcome of treatment and factors predicting results of sorafeni...
Tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of unresectable and metastatic...